CORIS BIOCONCEPT SPRL

Their core work

CORIS BIOCONCEPT is a Belgian SME specializing in rapid diagnostic test development, particularly lateral flow assays and point-of-care devices for infectious diseases. They develop printed biosensors and diagnostic platforms that enable bedside detection of pathogens like Ebola and other viral haemorrhagic fevers. More recently, they have expanded into paper-based electronics and smart labelling, combining their biosensor expertise with nanocellulose and printed electronics technologies.

What they specialise in

How they've shifted over time

In their early H2020 phase (2015–2018), CORIS focused squarely on infectious disease diagnostics — leishmaniasis and Ebola — working within traditional biomedical consortia. From 2018 onward, they branched into printed electronics and nanocellulose-based biosensors (INNPAPER), while continuing viral diagnostics work (VHFMoDRAD). This signals a deliberate move from purely biological assay development toward integrating advanced materials and printed electronics into their diagnostic platforms.

CORIS is evolving from a traditional diagnostic kit developer toward paper-based smart biosensors, positioning themselves at the intersection of printed electronics and point-of-care health technology.

How they like to work

CORIS operates exclusively as a consortium participant, never leading projects — typical for a specialist SME that brings specific technical capabilities rather than project management. With 66 unique partners across 18 countries from just 4 projects, they work in large, diverse consortia (averaging ~17 partners per project). This broad network suggests they are a sought-after specialist contributor rather than a company that repeatedly teams up with the same partners.

Despite only 4 projects, CORIS has built a remarkably wide network of 66 partners across 18 countries, reflecting the large international consortia typical of health and IMI-funded research. Their reach spans well beyond Western Europe into global health research networks.

What sets them apart

CORIS sits at a rare intersection: they combine hands-on expertise in infectious disease lateral flow assays with emerging capabilities in printed electronics and nanocellulose-based biosensors. Few diagnostic SMEs can bridge biological assay development and advanced materials/printed sensor fabrication. For consortium builders, they offer a practical, industry-side partner who can take biosensor concepts from lab prototyping toward manufacturable point-of-care products.

Highlights from their portfolio

• INNPAPER
  Their largest funded project (EUR 479K) and a strategic pivot — applying their biosensor expertise to nanocellulose-based printed electronics and smart labelling.
• VHFMoDRAD
  Demonstrates end-to-end diagnostic development capability: multiplex detection, RPA/LFA technologies, non-human primate validation, and capacity building for field deployment.